NCT00495391 - Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions

Chronic Hepatitis C

Interventions

DRUG

Nitazoxanide

One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.

DRUG

Placebo

One oral placebo tablet twice daily for 52 weeks.

BIOLOGICAL

Peginterferon alfa-2a

Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.

DRUG

Ribavirin

1000 mg (if \<75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.

Trial Locations (10)

10021

Weill Cornell Medical College, New York

23249

McGuire VA Medical Center, Richmond

30308

Atlanta Gastroenterology Associates, Atlanta

32610

University of Florida Hepatology, Gainesville

33777

Florida Center for Gastroenterology, Largo

37205

Nashville Medical Research Institute, Nashville

78234

Brooke Army Medical Center, Fort Sam Houston

94304

VA Palo Alto Healthcare System, Palo Alto

94305

Stanford University School of Medicine, Stanford

06520

Yale University Digestive Diseases, New Haven

All Listed Sponsors

lead

Romark Laboratories L.C.

INDUSTRY